Transactions
7
Insider / Praxis Precision Medicines, Inc.
Kelly Timothy Edwin
Chief Financial Officer at Praxis Precision Medicines, Inc.
- Ticker
- PRAX
- First filing on record
- November 21, 2025
- Latest trade on record
- May 14, 2026
- SEC filings
- EDGAR ↗
Kelly Timothy Edwin, Chief Financial Officer at Praxis Precision Medicines, Inc., has disclosed 7 transactions in PRAX since November 21, 2025: 0 purchases (0 open-market buys) and 3 sales, worth about $718K at the reported prices. The latest was filed May 19, 2026, 5 days after the trade; 2 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
0
Sales
3
Avg. disclosure lag
3.6d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Kelly Timothy Edwin made no purchases and 3 sales worth $686K, plus 4 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Kelly Timothy Edwin has traded 1 stock on record; the largest by dollars is PRAX.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
2 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 4 | 16,345 | $32K |
| F | Shares withheld for tax | 3 | 2,417 | $686K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 6 | 0 | 3 · $686K |
| 2025 | 1 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| PRAX | Other A | May 14, 2026 | May 19, 2026 | 5d | 121 | $168 | $20K | late | Form 4 ↗ | |
| PRAX | Sell F | January 12, 2026 | January 13, 2026 | 1d | 943 | $276 | $260K | Form 4 ↗ | ||
| PRAX | Other A | January 8, 2026 | January 12, 2026 | 4d | 7,040 | — | — | derivative | Form 4 ↗ | |
| PRAX | Sell F | January 10, 2026 | January 12, 2026 | 2d | 1,335 | $288 | $385K | Form 4 ↗ | ||
| PRAX | Other A | January 8, 2026 | January 12, 2026 | 4d | 8,800 | — | — | Form 4 ↗ | ||
| PRAX | Sell F | January 7, 2026 | January 9, 2026 | 2d | 139 | $293 | $41K | Form 4 ↗ | ||
| PRAX | Other A | November 14, 2025 | November 21, 2025 | 7d | 384 | $32 | $12K | late | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 19, 2026 | Form 4 | 0001689548-26-000050 | 1 | published | EDGAR ↗ |
| January 13, 2026 | Form 4 | 0001863297-26-000005 | 1 | published | EDGAR ↗ |
| January 12, 2026 | Form 4 | 0001689548-26-000011 | 3 | published | EDGAR ↗ |
| January 9, 2026 | Form 4 | 0001863297-26-000002 | 1 | published | EDGAR ↗ |
| November 21, 2025 | Form 4 | 0001104659-25-115100 | 1 | published | EDGAR ↗ |
Other insiders at Praxis Precision Medicines, Inc.
- Mastrocola Lauren Principal Accounting Officer 22 rows
- Nemiroff Alex General Counsel and Secretary 20 rows
- DeSimone Jill Director 18 rows
- Adage Capital Management, L.P. Insider 10 rows
- Souza Marcio Chief Executive Officer 8 rows
- Norden Gregory Director 7 rows
- Arbuckle Stuart A Director 5 rows
- KINDLER JEFFREY B Director 5 rows
- Sniecinski Megan Chief Operating Officer 5 rows
- Chodakewitz Jeffrey Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: Praxis Precision Medicines, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 7 | November 21, 2025 | May 19, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.